Oral drug for ulcerative colitis safety study
Part of Digestive system clinical trials.
This study tests an investigational oral drug for ulcerative colitis. It is an early-stage trial to check safety and how the drug is processed by the body in both healthy volunteers and patients with active ulcerative colitis.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Adults aged 18 and older (healthy volunteers: 18 to 55)
- For healthy volunteers: must be generally healthy, with a body mass index between 18.0 and 32.0
- For patients: must have a diagnosis of ulcerative colitis for at least 3 months
- No prior major colon surgery for ulcerative colitis
- No recent changes to certain UC medications (like steroids, biologics, or immunosuppressants)
- Willing to abstain from alcohol and recreational drugs for a long period, and avoid pregnancy
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an investigational pill for people with moderate-to-severe ulcerative colitis that has not improved with standard treatments. The goal is to see if the pill can reduce symptoms like bloody stools and frequent bowel movements.
This trial tests a new oral medication for people with active ulcerative colitis that hasn't responded well to standard treatments. The goal is to see if the drug reduces inflammation and improves symptoms.
This trial tests an oral study drug called Hemay005 for people with moderate to severe ulcerative colitis (UC) who have not responded well to other treatments. If you join, you will receive either the study drug or a placebo (inactive pill) to see if it helps reduce symptoms and heal the gut lining.
This study tests a new medication (called 627) for people with moderate to severe ulcerative colitis who haven't responded well to or couldn't tolerate other treatments. The goal is to see if it can safely reduce inflammation and improve symptoms.
This study tests an investigational pill (PTT-621) for moderate to severe ulcerative colitis that hasn't responded well to standard treatments. It aims to see if the drug can reduce inflammation and improve symptoms, while checking safety and how the body handles it.
This trial tests a new medicine, ENC1018, taken by mouth, for people with moderate to severe ulcerative colitis (UC) that hasn't improved with standard treatments. The goal is to see if it's safe and helps reduce symptoms.
Hear when a new Ulcerative Colitis (UC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.